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The evolution of natriuretic peptide augmentation in 
management of heart failure and the role of sacubitril/
valsartan
Srikanth Yandrapalli, Wilbert S. Aronow, Pratik Mondal, David R. Chabbott
A b s t r a c t
Heart failure (HF) is one of the leading causes of morbidity, mortality, and 
health care expenditures in the US and worldwide. For three decades, the 
pillars of treatment of HF with reduced ejection fraction (HFrEF) were med-
ications that targeted the sympathetic nervous system (SNS) and the re-
nin-angiotensin-aldosterone system (RAAS). Prior attempts to augment the 
natriuretic peptide system (NPS) for the management of HF failed either due 
to lack of significant clinical benefit or due to the unacceptable side effect 
profile. This review article will discuss the NPS, the failure of early drugs 
which targeted the NPS as therapies for HF, and the sequence of events 
which led to the development of sacubitril plus valsartan (Entresto; LCZ696; 
Novartis). LCZ696 has been shown to be superior to the standard of care 
available for treatment of HFrEF in several substantial hard endpoints in-
cluding heart failure hospitalizations, cardiovascular mortality, and all-cause 
mortality.
Key words: sacubitril/valsartan, Entresto, LCZ696, heart failure with 
reduced ejection fraction, natriuretic peptide system.
Introduction
Heart failure (HF) is the inability of the heart to pump an adequate 
supply of blood to meet the demands of the body. The HF is a clinical 
syndrome characterized by impaired myocardial function and progres-
sive maladaptive neurohormonal activation of the cardiovascular and 
renal systems leading to circulatory insufficiency. The HF is one of the 
leading causes of morbidity, mortality, and health care expenditures in 
the US and worldwide [1–4]. The HF is classified on the basis of ejection 
fraction (EF) into HF with reduced EF (HFrEF) with an EF < 50%, and HF 
with preserved EF (HFpEF) with an EF ≥ 50%. Over the last century there 
has been significant progress in identifying the neurohormonal systems 
responsible for the development of heart failure including the sympa-
thetic nervous system (SNS) and the renin-angiotensin-aldosterone sys-
tem (RAAS) (Figure 1). Beta-adrenergic blockers (β-blockers) targeting 
the SNS, angiotensin-converting enzyme inhibitors (ACEIs), angioten-
sin receptor blockers (ARBs), and aldosterone antagonists targeting the 
RAAS have become the cornerstone of medical therapy for chronic HFrEF 
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[5]. These drugs have been shown to reduce both 
morbidity and mortality [5]. However, with im-
proved survival of patients with acute myocardial 
infarction and a growing elderly population, heart 
failure will continue to increase in prominence as 
a major health issue in the United States and the 
world [1]. 
The newest and most promising medication 
for the treatment of chronic HFrEF is sacubitril/
valsartan (LCZ696), a  drug that targets the na-
triuretic peptide system (NPS) in addition to the 
RAAS (Figure 1) [6]. This article will briefly discuss 
the NPS, explain the reasons behind the failure of 
the early agents that targeted the NPS, and will 
then proceed to review the development and cur-
rent physiological understanding of LCZ696 in the 
treatment of HF.
Treatment of heart failure
The HF as a disease entity was first described 
in texts dating back to ancient Egypt, Greece, and 
India [7]. The first medical therapy for HF was dig-
italis, an extract from the Foxglove plant [8]. From 
the early 1900s, diuretics were used in addition to 
digoxin [9]. These medications treated the symp-
toms of HF and did not target the neuro-hormonal 
pathways causing the HF syndrome. Since then, 
ACEIs [10, 11], β-blockers [12–14], aldosterone an-
tagonists [15–17], ARBs [18, 19], and the combi-
nation of isosorbide dinitrate and hydralazine [20] 
have been approved for the treatment of HFrEF.
Natriuretic peptide system (NPS) 
Currently, the cornerstones of HF therapy are 
drugs that modulate the SNS and RAAS. Howev-
er, since the early 1980s, there has been signifi-
cant clinical interest in the NPS as a key hormonal 
pathway critical to the development and possible 
treatment of HF. Natriuretic peptides (NPs) are 
endogenous protein molecules that cause urinary 
sodium excretion, with the exception being C-type 
NP, which does not exert a marked effect on sodi-
um or water excretion [21]. The NPS consists of the 
three main NPs secreted from the heart: atrial na-
triuretic peptide (ANP), B-type natriuretic peptide 
(BNP), and C-type natriuretic peptide (CNP) [22]. 
ANP is primarily secreted from the atria, BNP from 
the ventricles and CNP from endothelial cells and 
cardiac fibroblasts [22]. ANP and BNP are circulat-
ing hormones released from the atrium and ven-
Figure 1. Neuro-hormonal interactions in heart failure and their role in contributing to the progression of heart fail-
ure. Heart failure activates the SNS and the RAAS, which leads to increased sympathetic tone and vasoconstriction, 
thereby increasing the afterload on the failing heart. RAAS activation leads to an increase in secretion of aldoste-
rone and ADH causing fluid retention, edema, and fibrotic changes in the failing myocardium. Together, the SNS 
and the RAAS result in pathophysiological and clinical worsening of HF. ACEI, ARB, MRA, and BB reduce the effects 
of the RAAS and the SNS. The failing heart also activates the NPS, which promotes sodium and water excretion, 
vasodilatation, and decreased aldosterone secretion, and inhibits fibrotic changes in the failing myocardium. The 
effects of the NPS are antagonistic to those of the SNS and the RAAS. LCZ696 acts by augmenting the NPS and 
inhibiting the RAAS, thereby improving the symptoms and inhibiting the progression of HF
NPS – natriuretic peptide system, RAAS – renin-angiotensin-aldosterone system, SNS – sympathetic nervous system,  
ACEI – angiotensin converting enzyme inhibitor, ARB – angiotensin receptor blocker, MRA – mineralocorticoid receptor antagonist, 
BB – β-adrenergic blocker, ADH – antidiuretic hormone, “+” indicates augmentation, “–” indicates inhibition, “↑” indicates 
increase, “↓” indicates decrease.
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tricles in response to stretch and fluid overload, 
and these hormones counteract the volume over-
loaded state by promoting natriuresis, diuresis, 
vasodilation, and RAAS blockade via aldosterone 
and renin inhibition [22]. ANP and BNP decrease 
preload via diuresis and decrease afterload via 
vasodilation and RAAS blockade. CNP acts local-
ly and exhibits vasodilatory and anti-remodeling 
effects on the myocardium [23]. These hormonal 
actions prevent the classic pathologic structur-
al changes associated with HF including cardio-
vascular remodeling, ventricular hypertrophy, and 
fibrosis [24].
In contrast to the detrimental effects of acti-
vation of the SNS and the RAAS, activation of 
the NPS appears to have a beneficial role in the 
prevention of progression of HF. Understanding 
of the beneficial effects of NPS prompted the cre-
ation of human synthetic ANP (carperitide) and 
human recombinant BNP (nesiritide). Intravenous 
infusion of carperitide is used as a  treatment 
for acute decompensated heart failure in Japan 
without good evidence to support this practice 
[25]. Although infusions of nesiritide have shown 
promising results in a few studies [26, 27], nesir-
itide failed to show significant clinical benefit in 
larger trials [28–30]. The ASCEND-HF (Acute Study 
of Clinical Effectiveness of Nesiritide and Decom-
pensated Heart Failure) trial compared nesiritide 
and placebo in the treatment of acute decompen-
sated heart failure. The results of this trial showed 
no significant benefit in early dyspnea relief, 30-
day mortality or readmission rates in the nesiriti-
de group, but showed an increase in hypotension 
[28]. On the basis of the available data the NPs 
were widely accepted as biomarkers of HF but not 
therapeutic options [5]. 
Neprilysin inhibition
When intravenous infusion of NPs did not 
demonstrate significant clinical significance in 
treating HF, the focus shifted to developing inhib-
itors of enzymes that degrade endogenous NPs. 
Clearance of circulating NPs is via receptor-me-
diated clearance and enzymatic degradation by 
extracellular proteases [31]. Neprilysin (NEP) is 
a  large membrane-bound neutral endopeptidase 
responsible for cleaving NPs [31]. NEP, also known 
as enkephalinase, atriopeptidase, EC 3.4.24.11, 
and CD10 [31], is present in many tissues [24, 32], 
and is most abundant in the renal cortex [33]. NEP 
contributes to the extremely short half-life of ANP 
of approximately 2 min [33]. ANP and CNP are 
more readily degraded, whereas BNP is relatively 
resistant to the action of NEP [34]. From a physi-
ologic standpoint, inhibiting NEP represented an 
approach to augment endogenous NP levels and 
activity. 
Thiorphan, an NEP inhibitor (NEPI), was syn-
thesized in 1980 [35], and subsequent studies in 
animals [36] and humans [37] demonstrated that 
NEP inhibition increased ANP levels with associat-
ed natriuresis, diuresis and blood pressure reduc-
tion. Additionally, NEP inhibition suppressed the 
activation of aldosterone [38], demonstrating the 
important interaction between NPS and the RAAS 
[33]. In a study of 9 patients with severe chronic 
HF (EF < 30%), intravenous candoxatrilat (an NEPI) 
increased circulating ANP, improved natriuresis 
and diuresis, and reduced right atrial pressure and 
pulmonary capillary wedge pressure, without af-
fecting the arterial blood pressure [39]. The posi-
tive results from this trial prompted investigations 
using oral NEPIs. However, studies of oral ecadotril 
[40, 41] and oral candoxatril [42] failed to show 
significant benefit in patients with chronic HF and 
essential hypertension, respectively. A  few stud-
ies showed inconsistent effects of NEPIs on blood 
pressure [42, 43].
In addition to degrading NPs, NEP also de-
grades a  large number of other vasoactive pep-
tides including vasodilators such as adrenomedul-
lin and bradykinin and vasoconstrictors such as 
angiotensin I, II, and endothelin-1 [44, 45]. The 
beneficial effects of augmenting endogenous NPs 
were offset by the NEPI-mediated enhancement 
of vasoconstrictor substances, importantly angio-
tensin II, and, thereby, enhancing the RAAS. Based 
on these observations, it was evident that lone 
NEP inhibition showed little effect on blood pres-
sure and only modest benefits [45] in the treat-
ment of HF (Figure 2). 
The rise and fall of omapatrilat
The rational solution to this dilemma was to 
further inhibit angiotensin II in addition to NEP in 
an effort to prevent the detrimental effects of NEP 
inhibition on the RAAS. Preliminary animal studies 
with combined selective NEPI and captopril (an 
ACEI) showed greater blood pressure reduction 
[46], improved systemic hemodynamics [47], and 
improved left atrial filling pressures [48]. 
After the synthesis of an orally active combined 
ACEI-NEPI in 1994 [49], multiple studies examined 
the effects of an orally active vasopeptidase inhib-
itor – omapatrilat. This class of drugs was referred 
to as vasopeptidase inhibitors as they have dual 
inhibitory effects on 2 key enzymes involved in the 
metabolism of vasoactive peptides [50]. Omapa-
trilat improved natriuresis, diuresis, left ventricu-
lar EF, and functional class in chronic HF patients 
[51]. The IMPRESS (Inhibition of Metallo Protease 
by BMS-186716 in a  Randomized Exercise and 
Symptoms Study in Subjects With Heart Failure) 
trial, a phase II randomized clinical trial that com-
pared omapatrilat with lisinopril in 573 HFrEF pa-
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tients, showed that omapatrilat had a non-signif-
icant benefit in the composite of first occurrence 
of death or admission for worsening HF [52, 53]. 
The OVERTURE (Omapatrilat Versus Enalapril 
Randomized Trial of Utility in Reducing Events) tri-
al was a  phase III randomized double-blind trial 
that compared omapatrilat with enalapril in 5770 
patients with New York Heart Association (NYHA) 
class II–IV HF for a mean duration of 14.5 months 
[54]. Results from the OVERTURE trial showed that 
omapatrilat was neither superior nor inferior to 
enalapril in reducing the primary endpoint of com-
bined all-cause mortality and HF hospitalizations 
requiring intravenous treatment [54]. Post hoc 
analysis using a broader definition for HF hospi-
talizations (as used in the Studies of Left Ventric-
ular Dysfunction (SOLVD) treatment trial) showed 
a 11% reduction (nominal p = 0.012) in the prima-
ry endpoint [54]. Secondary analysis favored oma-
patrilat in reducing cardiovascular-related death 
or cardiovascular-related hospitalizations [54]. 
Although the adverse effect profiles were simi-
lar, angioedema was more frequent in patients 
taking omapatrilat (0.8%) compared to the enal-
april group (0.5%). Encouraging results from the 
OVERTURE trial prompted larger clinical trials. 
The Omapatrilat Cardiovascular Treatment vs. 
Enalapril (OCTAVE) trial was a  randomized, con-
trolled, double-blind trial that compared omapa-
trilat and enalapril for 24 weeks in 25,302 hy-
pertensive patients [55]. Although omapatrilat 
significantly lowered blood pressure, angioede-
ma was more frequent with omapatrilat (2.17%) 
than with enalapril (0.68%), particularly in Afri-
can-Americans (5.53% vs 1.62%) [55]. 
ACEI can potentially cause angioedema by in-
hibiting the metabolism of bradykinin [56, 57]. 
Subsequently, it was identified that omapatrilat 
also inhibits aminopeptidase P(APP), which is in-
volved in bradykinin metabolism [58]. Bradykinin 
is inactivated by various enzymes including ACE, 
NEP, and APP, all of which are inhibited by oma-
patrilat [59]. The synergism of ACE inhibition with 
NEP inhibition led to a large increase in the levels 
of bradykinin [59], causing angioedema, a  con-
cern that stalled the approval and further devel-
opment of a combined ACEI-NEPI as a therapy for 
HF (Figure 2).
LCZ696 and the early clinical trials
The discovery of the role of NPS in the progres-
sion of HF and the idea of combined RAAS and 
Figure 2. Physiological mechanisms behind the failure of lone neprilysin inhibition, and combined angiotensin 
converting enzyme – neprilysin inhibitors, as potential therapies in the management of heart failure. The beneficial 
effects of augmenting endogenous natriuretic peptides with NEPI were offset by the NEP-mediated enhancement 
of vasoconstrictor substances, especially AT-II, which enhanced the RAAS pathway. Bradykinin is inactivated by 
various enzymes including ACE, NEP, and APP, all of which are inhibited by omapatrilat. The synergism of ACE inhi-
bition with NEP inhibition led to a large increase in the levels of bradykinin, thereby causing angioedema
NPS – natriuretic peptide system, ANP – A-type natriuretic peptide, BNP – B-type natriuretic peptide, CNP – C-type 
natriuretic peptide, RAAS – renin-angiotensin-aldosterone system, AT-I – angiotensin I, AT-II – angiotensin II, NEP – neprilysin,  
ACE – angiotensin converting enzyme, APP – aminopeptidase P, ACEI – angiotensin converting enzyme inhibitor, NEPI – neprilysin 
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NEP inhibition remained exciting and promising, 
but the trials discussed demonstrated that oma-
patrilat was associated with angioedema [55]. The 
logical solution to this problem was a combination 
of an ARB and NEPI which would inhibit the RAAS 
and enhance the NPS without inhibiting ACE or 
APP. By using this combination, the endogenous 
bradykinin would be metabolized by the uninhib-
ited ACE, thereby not greatly increasing the risk of 
angioedema. Results from an animal study pub-
lished later supported this hypothesis [60]. 
LCZ696 is a  novel, orally active, first-in-class 
angiotensin receptor-neprilysin inhibitor (ARNI) 
which combines valsartan (an ARB) and sacubitril 
in a 1 : 1 ratio [61]. Sacubitril (AHU377) is a pro-
drug, which upon ingestion is rapidly metabolized 
to an active NEPI moiety, LBQ657 [61]. Phase I and 
II studies of LCZ696 showed that after oral admin-
istration of LCZ696, peak plasma concentrations 
were reached rapidly for valsartan (1.6–4.9 h), 
sacubitril (0.5–1.1 h), and its active moiety LBQ657 
(1.8–3.5 h), followed by an acute blood pressure 
reduction [61]. LCZ696 treatment was associated 
with increases in plasma ANP and cGMP, diuresis, 
blood pressure reduction, increased renin concen-
tration and activity, and increased angiotensin II 
levels, providing evidence for NEP inhibition and 
angiotensin receptor blockade [61, 62]. LCZ696 
was considered safe and well tolerated, and data 
from these studies supported its further clinical 
development for hypertension and HF.
A phase III trial compared LCZ696 with valsar-
tan in 1328 subjects with mild to moderate hyper-
tension [63]. The primary endpoint of this study 
was the mean difference across the 3 single-dose 
pairwise comparisons of LCZ696 versus valsar-
tan (100 mg vs. 80 mg, 200 mg vs. 160 mg, and 
400 mg vs. 320 mg) in mean sitting diastolic blood 
pressure during the 8-week treatment period. Part 
of the study population received either AHU377 or 
placebo once daily. Data from this study showed 
that reduction in systolic, diastolic, and pulse pres-
sures, both sitting and ambulatory, was greater 
with LCZ696 than with either valsartan or AHU377 
[63]. A similarly designed trial comparing LCZ696 
with placebo in 389 Asian subjects with mild to 
moderate hypertension achieved similar results 
[64]. Although LCZ696 was well tolerated in both 
trials without reports of angioedema, only a small 
percentage of study patients were black [63, 64], 
in whom the incidence of angioedema was great-
er according to the OCTAVE trial [65]. Also the gen-
eralizability of these data to patients with HF is 
limited because such patients were excluded from 
these trials.
The PARAMOUNT (Prospective comparison of 
ARNI with ARB on Management Of heart failUre 
with preserved ejectioN fracTion) trial was a phase II 
randomized double-blind trial of 301 patients 
with NYHA class II–IV HFpEF that compared N-ter-
minal pro BNP (NT-proBNP) levels after 12 weeks 
of treatment with either LCZ696 or valsartan [65]. 
NT-proBNP is a precursor molecule for BNP and is 
not a substrate for NEPI [66]. Baseline NT-proBNP 
was greater than 400 pg/ml in the study population. 
At 12 weeks, NT-proBNP was significantly reduced 
in the LCZ696 group (hazard ratio (HR) = 0.77, 
p = 0.005). After 36 weeks of treatment, the 
LCZ696 group demonstrated a  decrease in left 
atrial volume and size and greater improvement in 
NYHA functional class. The adverse event rate was 
similar in both groups. Post hoc analysis suggest-
ed that the NT-proBNP lowering effect of LCZ696 
was independent of systolic blood pressure reduc-
tion [67]. Encouraging results from these early tri-
als prompted further larger trials.
The paradigm-heart failure trial
The medical and pharmaceutical community 
looked forward to further studies investigating 
the clinical benefit of LCZ696 in HF patients. The 
PARADIGM-HF (Prospective comparison of ARNI 
with ACEI to Determine Impact on Global Mortal-
ity and morbidity in Heart Failure) was a phase III 
double-blind trial that randomized 8442 patients 
with NYHA class II–IV HF and an EF of ≤ 40% 
(later amended to ≤ 35%) to receive twice daily 
dosing of either 200 mg of LCZ696 or 10 mg of 
enalapril in addition to standard medical thera-
py for HF [6]. Enalapril was chosen as it was the 
most widely studied RAAS blocker in patients with 
chronic HFrEF, and the target dose of enalapril in 
PARADIGM-HF was similar to the dose used in the 
SOLVD treatment trial. The majority of the study 
population was receiving β-blockers and miner-
alocorticoid receptor antagonists. The primary 
endpoint was a composite of death from cardio-
vascular causes or hospitalization for HF. 
The PARADIGM-HF trial was initiated without 
a phase-II safety trial and hence the investigators 
employed steps to test the tolerability of LCZ696 
before randomization. Patients taking any dose 
of ACEI or ARB were considered for participa-
tion in the study, but prior to screening, patients 
were required to be on a stable dose of an ACEI 
or an ARB that was the therapeutic equivalent of 
10 mg of enalapril daily for at least 4 weeks. Patients 
that met screening criteria then entered an initial 
run-in period where they were switched from their 
prior ARB or ACEI to 10 mg of enalapril twice daily 
for 2 weeks. If this regimen was tolerated, a sec-
ond run-in period was implemented where partic-
ipants were started on a single blind treatment of 
LCZ696 for an additional 4–6 weeks. Initially the 
dose of LCZ696 was 100 mg twice daily, which was 
increased to 200 mg twice daily. If participants tol-
erated both the study medications (LCZ696 and 
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enalapril), they were then randomly assigned 
to double-blind treatment with either enalapril 
10 mg twice daily or LCZ696 200 mg twice daily. 
This methodology allowed the investigators to ob-
tain data regarding the safety and tolerability of 
target doses of the study drugs. 
The study was stopped early after a median fol-
low-up of 27 months due to the significant clinical 
benefit observed with LCZ696, which at that time 
met the pre-specified cutoff for an immense bene-
fit. At 27-month follow-up, LCZ696 was associated 
with a 20% (HR = 0.80, p < 0.001) decrease in the 
primary endpoint compared to enalapril (absolute 
risk reduction (ARR) 4.7%). The number needed 
to treat over 27 months to prevent 1 occurrence 
of a  primary endpoint was 21. When compared 
to enalapril, LCZ696 reduced death from any car-
diovascular cause by 20% (ARR 3.2%, HR = 0.8, 
p < 0.001) and HF hospitalizations by 21% 
(HR = 0.79, p < 0.001), and improved the symptoms 
and quality of life as measured on the Kansas City 
Cardiomyopathy Questionnaire. There was a 16% 
(HR = 0.84, p < 0.001) reduction in all-cause mor-
tality in the LCZ696 arm. In terms of side effects, 
14% of patients receiving LCZ696 experienced hy-
potension compared to 9% in the enalapril group 
(p < 0.001). However, the number of patients who 
discontinued therapy due to hypotension was not 
significantly different (0.9% in the LCZ696 group 
vs. 0.7% in the enalapril group). Non-serious an-
gioedema occurred more frequently in the LCZ696 
group although the difference was not significant 
(19 cases vs. 10 cases in the enalapril group). Sig-
nificantly fewer patients developed cough (11.3% 
in the LCZ696 group vs. 14.3% in the enalapril 
group, p < 0.001), elevated serum potassium 
> 6.0 mmol/l (4.3% in the LCZ696 group vs. 5.6% 
in the enalapril group, p = 0.007), or elevated se-
rum creatinine ≥ 2.5 mg/dl (3.3% in the LCZ696 
group vs. 4.5% in the enalapril group, p = 0.007) in 
the LCZ696 group.
Additional analysis of the paradigm-heart 
failure trial
The PARADIGM-HF investigators also compared 
the effects of LCZ696 with putative placebos us-
ing the treatment arms of the SOLVD treatment 
trial and the Candesartan in Heart Failure-As-
sessment in Reduction in Mortality and Morbid-
ity-Alternative (CHARM-Alternative) trial as ref-
erences for comparison with enalapril (an ACEI) 
and candesartan (an ARB), respectively [68]. For 
the primary composite outcome of cardiovascular 
death or HF hospitalization in the PARADIGM-HF 
trial, the relative risk reduction with LCZ696 ver-
sus a putative placebo from the SOLVD treatment 
trial was 43% (p < 0.0001) with similarly large ef-
fects on cardiovascular death (34%; p < 0.0001), 
heart failure hospitalization (49%; p < 0.0001), 
and all-cause mortality (28%; p < 0.0001). Puta-
tive placebo analyses based on the CHARM-Alter- 
native trial showed relative risk reductions of 39% 
(p < 0.0001) for the composite outcome of car-
diovascular death or heart failure hospitalization, 
32% (p < 0.0001) for cardiovascular death, 46% 
(p < 0.0001) for heart failure hospitalization, and 
26% (p < 0.0001) for all-cause mortality [68].
Secondary analyses of data from the PARADIGM- 
HF trial were also encouraging. When compared 
to enalapril, LCZ696 exhibited additional clinical 
benefits in parameters that quantify HF disease 
progression, including reduced worsening of NYHA 
functional class (≥ 1 class) at 1 year (p = 0.023), 
reduced need for intensification of medical treat-
ment of HF (HR = 0.84, p = 0.003) and reduced 
requirement of intensive care (18% rate reduction; 
p = 0.005) or intravenous inotropic support (31% 
risk reduction, p < 0.001) [69]. LCZ696 was asso-
ciated with significant reductions in emergency 
department visits (HR = 0.66; p = 0.001) and 23% 
fewer hospitalizations for worsening HF (p < 0.001) 
[69]. Significant reductions in the levels of NT-proB-
NP and troponins were observed, which indicates 
reduced heart stress. Non-significant reductions 
in the need for implantation of a  HF device and 
cardiac transplantation were also observed [69]. 
LCZ696 was superior to enalapril in reducing both 
sudden cardiac death (HR = 0.80, p = 0.008) and 
death from worsening heart failure (HR = 0.79, 
p = 0.034), independent of whether the patient 
had an implantable cardioverter-defibrillator [70]. 
The superiority of LCZ696 over enalapril was ap-
parent irrespective of glycemic status [71], left ven-
tricular EF [72], HF risk scores [73], systolic blood 
pressure [74], and age [75]. 
LCZ696 investigated at the tissue level
Investigators examined the mechanistic ac-
tions of LCZ696 at the tissue level. Von Lueder 
et al. randomized post-myocardial infarction 
adult male Sprague-Dawley rats to treatment for 
4 weeks with LCZ696 or a vehicle [76]. At the con-
clusion of the study, the LCZ696 group demon-
strated higher left ventricular EF and function, 
lower left ventricular end diastolic diameter, and 
lower heart mass. Additionally, the LCZ696 group 
had markedly reduced fibrosis in the peri-infarct 
area and remote myocardium, which can be inter-
preted as reduced cardiac remodeling. This study 
demonstrated the ARNI-mediated inhibition of 
hypertrophy and fibrosis leading to attenuation of 
cardiac remodeling and myocardial dysfunction. 
Suematsu et al. investigated the effects of LCZ696 
therapy in diabetic mice with HFrEF in compari-
son with valsartan or control [77]. In this study, 
LCZ696 improved cardiac function with the reduc-
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tion of fibrosis. The investigators attributed this 
to the suppression of local transforming growth 
factor-β by the sacubitril moiety of LCZ696. These 
studies further support the pathophysiological ba-
sis for the beneficial effects of LCZ696 observed in 
the PARADIGM-HF trial.
Criticism of the PARADIGM-HF trial 
The PARADIGM-HF trial is not without criticism, 
especially in regards to the study population. The 
study population in the PARADIGM-HF trial was 
predominantly white (66%), male (78%), NYHA 
functional class II HF (70%), and had a mean age 
of 64 years. Only 60 patients (< 1%) had NYHA 
functional class IV HF at baseline, and only 5% 
of the study population was black. These factors 
might reduce the generalizability of the data from 
the trial as HF patients are usually older individ-
uals with varying NYHA functional class. In the 
United States population, non-Hispanic black pa-
tients have a higher rate of HF-related mortality as 
compared to others [4]. In the OCTAVE trial, black 
patients had an increased frequency of angioede-
ma with omapatrilat [55]. The lower proportion of 
black patients in the PARADIGM-HF trial may have 
limited the ability of this trial to detect a signifi-
cant difference in the frequency of angioedema 
with LCZ696.
It is also important to consider the high drop-
out rate of 20% during the run-in phases in the 
study [6]. This dropout rate may reduce the gen-
eralizability of the study to the target patient pop-
ulation. Physicians should thereby be cautious in 
selecting patients for treatment with LCZ696, as 
a  significant number of HF patients may not be 
able to tolerate the drug, and a run-in period is not 
feasible in regular clinical practice.
Lastly, NEP plays a  critical role in maintaining 
the homeostasis of amyloid-β peptide (Aβ) in the 
brain [78]. NEPI might lead to accumulation of 
Aβ in the brain, favoring the development of Alz-
heimer’s dementia [79]. Although the incidence 
of cognition-related adverse effects was not in-
creased by LCZ696 in the PARADIGM-HF trial [6], 
the duration of the trial was not long enough to 
assess this problem. Such data should be available 
from the PARAGON-HF (Prospective comparison of 
angiotensin receptor-neprilysin inhibitor with ARB 
Global Outcomes in HF with preserved ejection 
fraction) trial (NCT01920711), which includes se-
rial cognitive function testing in its design. Also 
phase IV safety data of LCZ696 might shed more 
light on this association.
Current role of LCZ696 in heart failure  
and the future of LCZ696
The United States Food and Drug Administra-
tion approved LCZ696 for the treatment of HF. 
Although the drug is not yet approved for clinical 
use in Canada , the Canadian HF guidelines rec-
ommend the use of LCZ696 in place of an ACEI or 
an ARB in patients with mild to moderate HF, an 
ejection fraction < 40%, an elevated natriuretic 
peptide level or hospitalization for HF in the past 
12 months, serum potassium < 5.2 mmol/l, and an 
estimated glomerular filtration rate ≥ 30 ml/min 
and treated with appropriate doses of guideline-di-
rected medical therapy, with close surveillance of 
serum potassium and creatinine (Conditional Rec-
ommendation; High-Quality Evidence) [80]. 
Further studies are testing LCZ696 on more se-
lective patient populations. The PARAMETER (Pro-
spective Comparison of an Angiotensin-Receptor 
Neprilysin Inhibitor With an Angiotensin-Receptor 
Blocker Measuring Arterial Stiffness in the Elder-
ly) study was designed to assess the short-term 
(12 weeks) and long-term (52 weeks) effects of 
LCZ696 compared with olmesartan (an ARB), on 
measures of central aortic hemodynamics and ar-
terial stiffness in older patients with systolic hy-
pertension and an increased pulse pressure [81]. 
The study met the primary endpoint of signifi-
cant reduction in central aortic systolic pressure 
with 12 weeks monotherapy in the LCZ696 group 
compared to the olmesartan group, although 
this significance did not persist at 52 weeks 
[81]. The phase III PARAGON-HF trial is currently 
recruiting participants to evaluate the efficacy 
and safety of LCZ696 compared to valsartan on 
morbidity and mortality in NYHA class II–IV HF 
patients with a  left ventricular EF > 45% (Clini-
calTrials.gov NCT01920711). This trial is based 
on the results from the PARAMOUNT trial. The UK 
Heart and Renal Protection III (UK HARP-III) trial 
(ISRCTN 11958993) will compare LCZ696 against 
irbesartan (an ARB) in patients with proteinuric 
chronic kidney disease to assess the short-term 
safety and efficacy of LCZ696 in this population 
[82]. If the results from the UK HARP-III trial favor 
LCZ696, longer duration studies to evaluate the 
effects of LCZ696 in delaying the progression of 
CKD to end-stage renal disease can be planned. 
Such beneficial effects can improve outcomes of 
HF patients with concomitant CKD.
Conclusions
The treatment of HF has been revolutionized 
with medications physicians are familiar with and 
trust such as the β-blockers, the ACEIs, the ARBs 
and aldosterone antagonists. Despite pharmaco-
logical advances, HF continues to increase in inci-
dence and remains a  leading cause of morbidity 
and mortality and economic burden. In this sce-
nario, there is definitely a  need for newer ther-
apies that can reduce the burden of HF on the 
community. Although the initial attempts of NP 
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enhancement for HF management have failed, the 
combination RAAS inhibitor and NPS enhancer 
sacubitril/valsartan performed significantly bet-
ter than the current standard of care ACEI in the 
PARADIGM-HF trial. Although one trial might not 
be sufficient to change the guidelines, the results 
from the PARADIGM-HF trial provide affirmation 
that targeting the NPS in addition to the SNS and 
the RAAS provides substantial benefit to patients 
with HFrEF. Further large trials testing LCZ696 on 
specific patient populations will provide more 
data regarding the beneficial effects of combining 
NPS augmentation with RAAS inhibition in pa-
tients with cardiovascular disease. 
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